280E Updates: Rescheduling, Amending Returns, and Why Timing Matters - Sign up for our free webinar now!

280E Updates: Rescheduling, Amending Returns, and Why Timing Matters - Sign up for our free webinar now!

Oregon Bud Company | Cannabis Business Times

Sign in or create a free Cannabis Business Times account to continue reading

Continue to Site »
Site will load in 15 seconds

Continue to Site »X

Oregon Bud Company

November 7, 2017

Da 2 Fmt

Da 3 Fmt

280E Updates: Rescheduling, Amending Returns, and Why Timing Matters - Sign up for our free webinar!

PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder

Best Cannabis Companies to Work For

How to Turn LED Lighting Into a Strategic Cultivation Tool

Sens. Ted Budd and Pete Ricketts' Hemp Product Ban Amendment

NMAI Letter RE: Final Determination Regarding Idaho Medical Cannabis Act Initiative Petition

What Is Certified Human-Composed Creation and Why Is It Important?

Massachusetts State Ballot Law Commission Ruling on Cannabis Petition - July 21, 2026

NDASA and MMJ Response to DOJ's Schedule III Stay Opposition - July 16, 2026

Image Distillate

Image Trimmer Test

Massachusetts State Ballot Law Commission Notice of Hearing 26-06 - July 2026

Kevin Gilnack Objection to Massachusetts Cannabis Petition Filed With State Ballot Law Commission -- July 8, 2026

Massachusetts Elections Division Letter to Coalition for a Healthy Massachusetts - July 9, 2026

DOJ Response Opposing NDASA/MMJ's Motion to Stay Schedule III Order

PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder

The trial of PP-01 (CAN-004) advances an investigational, once-daily therapy for withdrawal symptoms in patients with cannabis use disorder.

Page 1 of 10